Varespladib is currently in Phase 2 clinical trials against snakebites in India and the US
Some patients benefit from microdose protocols (0.10.2 mg) or off-label dose adjustments based on biomarker response
On safety: all GLP-1 receptor agonists share a well-characterized side-effect profile (nausea, vomiting, diarrhea, constipation, abdominal pain, headache common
The authors found that the novel emulsifier blend was essentially odorless, with very faint color and proper slight taste
Notably, a study in A plaque-bearing Tg2576 mice, initiated at 14 months of age, showed no significant impact on relieving oxidative damage, even with elevated plasma melatonin levels [165]
10.12816/0003082 81 Mazibuko-MbejeS